Gossamer Bio News

Gossamer Bio Analyst Ratings

BenzingaApr 5 04:55 ET

Gossamer Bio Analyst Ratings

BenzingaMar 27 12:41 ET

Buy Rating Affirmed on Gossamer Bio With Promising Seralutinib Prospects in PAH Treatment Landscape

TipRanksMar 27 09:55 ET

Gossamer Bio (GOSS) Receives a Buy From Piper Sandler

TipRanksMar 27 07:06 ET

Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)

TipRanksMar 21 09:00 ET

Piper Sandler Sticks to Its Buy Rating for Gossamer Bio (GOSS)

TipRanksMar 13 06:55 ET

Barclays Keeps Their Hold Rating on Gossamer Bio (GOSS)

TipRanksMar 11 02:45 ET

Gossamer Bio Analyst Ratings

BenzingaMar 6 08:42 ET

Strong Buy Rating on Gossamer Bio Amidst Seralutinib's Promising Trials and Solid Financials

TipRanksMar 6 07:55 ET

Gossamer Bio Earns 'Buy' Rating From Analyst Citing Progress in Seralutinib Trials and Strategic Market Expansion

TipRanksMar 5 20:15 ET

Maintained Buy Rating on Gossamer Bio Amidst Anticipated Phase 3 PROSERA Trial Results

TipRanksMar 5 18:15 ET

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Neurogene (NGNE) and Gossamer Bio (GOSS)

TipRanksJan 8 06:30 ET

HC Wainwright & Co. Maintains Buy on Gossamer Bio, Raises Price Target to $10

BenzingaJan 8 06:27 ET

Gossamer Bio Analyst Ratings

BenzingaJan 8 06:26 ET

Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Gossamer Bio (GOSS) and 4D Molecular Therapeutics (FDMT)

TipRanksJan 4 07:21 ET

Gossamer Bio Analyst Ratings

BenzingaDec 19, 2023 08:38 ET

Analysts Are Bullish on These Healthcare Stocks: Gossamer Bio (GOSS), Viridian Therapeutics (VRDN)

TipRanksDec 19, 2023 06:50 ET

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Viracta Therapeutics (VIRX) and Gossamer Bio (GOSS)

TipRanksNov 14, 2023 03:30 ET

Accelerated Progress and Positive Outlook for Gossamer Bio's Seralutinib: A Buy Recommendation

TipRanksNov 10, 2023 11:15 ET

Wedbush Maintains Outperform on Gossamer Bio, Raises Price Target to $6

BenzingaNov 10, 2023 08:30 ET